LUMINEX CORP - FORM 8-K - EX-99.1 - EXHIBIT 99.1 - November 2, 2015

Attached files

file filename
8-K - FORM 8-K - LUMINEX CORPa2015-q3form8xk.htm


Exhibit 99.1

LUMINEX CORPORATION REPORTS 3RD QUARTER 2015 RESULTS


AUSTIN, Texas (November 2, 2015) - Luminex Corporation (NASDAQ:LMNX) today announced financial results for the third quarter ended September 30, 2015. Financial and operating highlights for the quarter include the following:

•
Increased third quarter 2015 revenue by 7 percent to $60.6 million, over the third quarter of 2014.
•
Increased Q3 2015 system sales by 26 percent to $9.6 million over the third quarter of 2014.
•
Grew third quarter 2015 assay revenue by 12 percent to $24.6 million over results from the third quarter of 2014.
•
Decreased operating expenses as a percentage of revenue to 53 percent for the third quarter of 2015, a 7 point improvement from the third quarter of 2014.
•
Improved operating profits for the quarter by 94% as a result of both increased revenues and significant expense control.
•
Delivered GAAP net income for the third quarter of $6.4 million, or $0.15 per diluted share. Non-GAAP net income for the third quarter was $9.3 million, or $0.22 per diluted share (see Non-GAAP reconciliation).
•
Cash and short and long-term investments at quarter’s end totaled approximately $136 million, an increase of approximately $28 million compared with year-end 2014.
•
Raising 2015 revenue guidance range to between $235 million and $238 million from the prior range of between $232 million and $236 million.
•
In October, Luminex submitted a 510(k) pre-market submission to the FDA for the ARIES® Group B Streptococcus (GBS) Assay.

“This was a record quarter for Luminex as the Company exceeded $60 million in revenue for the first time. Our solid performance in the quarter reflects the merits of our balanced business model and the focus on appropriate resource allocation. This coupled with the hard work of our dedicated employees resulted in an operating profit of approximately $10 million, nearly double the amount reported for the same period last year,” said Homi Shamir, President and Chief Executive Officer of Luminex. “We believe that the recent FDA clearance for our ARIES® system and ARIES® HSV 1 & 2 assay will prove to be an exciting milestone for the Company in the large, sample-to-answer molecular diagnostic market. We look forward to launching ARIES this week at the Association for Molecular Pathology meeting in our home town of Austin.”





REVENUE SUMMARY
(in thousands, except percentages)

 
Three Months Ended
 
 
 
 
 
September 30,
 
Variance
 
2015
 
2014
 
($)
 
(%)
 
(unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
System sales
$
9,622

 
$
7,624

 
$
1,998

 
26%
Consumable sales
10,940

 
12,124

 
(1,184
)
 
-10%
Royalty revenue
10,249

 
9,690

 
559

 
6%
Assay revenue
24,639

 
22,056

 
2,583

 
12%
All other revenue
5,151

 
5,190

 
(39
)
 
-1%
 
$
60,601

 
$
56,684

 
$
3,917

 
7%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended
 
 
 
 
 
September 30,
 
Variance
 
2015
 
2014
 
($)
 
(%)
 
(unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
System sales
$
22,129

 
$
22,328

 
$
(199
)
 
-1%
Consumable sales
32,714

 
37,521

 
(4,807
)
 
-13%
Royalty revenue
32,024

 
29,215

 
2,809

 
10%
Assay revenue
74,323

 
63,602

 
10,721

 
17%
All other revenue
16,069

 
16,211

 
(142
)
 
-1%
 
$
177,259

 
$
168,877

 
$
8,382

 
5%
 
 
 
 
 
 
 
 


Additional Financial Highlights:

•
Infectious disease assay sales were approximately 68 percent of total assay sales for the quarter and genetic testing assays were 32 percent.
•
Royalty revenues reflect total royalty-bearing end-user sales for the quarter of $120.8 million.
•
307 multiplexing analyzers were shipped during the quarter, which included 113 MAGPIX® systems, 164 LX systems, and 30 FLEXMAP 3D® systems.
•
Cash and investments at quarter-end totaled $135.6 million.
•
Days sales outstanding (DSO) was 40 days at quarter-end.


FINANCIAL OUTLOOK AND GUIDANCE

The Company updates its revenue guidance range for the full-year 2015 to between $235 million and $238 million.


CONFERENCE CALL

Management will host a conference call at 3:30 p.m. CST/4:30 p.m. EST, Monday, November 2, 2015 to discuss the operating highlights and financial results for the third quarter ended September 30, 2015. The conference call will be webcast live and may be accessed at Luminex Corporation’s website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the ‘replay’ link.





Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company’s xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company’s xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this release that express Luminex’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base of multiplexing systems; the development progress of our pipeline products, including ARIES and NxTAG products, market acceptance of our products, including instruments, consumables and assays, regulatory clearance of our products; the ability of our investment in current initiatives and new products to drive long-term value for our shareholders; and, projected 2015 performance, including revenue guidance. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex’ products and technology in development, including ARIES and NxTAG, the uncertainty relating to increased focus on direct sales to the end user, dependence on strategic partners for development, commercialization and distribution of products, concentration of Luminex’ revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex’ technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges, the timing of and process for regulatory approvals, the impact of the ongoing uncertainty in global finance markets and changes in governmental funding, including its effects on the capital spending policies of Luminex’ partners and end users and their ability to finance purchases of Luminex’ products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, fluctuations in bulk purchases of consumables, fluctuations in product mix, and the seasonal nature of some of Luminex’ assay products, Luminex’ ability to obtain and enforce intellectual property protections on Luminex’ products and technologies, risks and uncertainties associated with implementing Luminex’ acquisition strategy, including Luminex’ ability to obtain financing, Luminex’ ability to integrate acquired companies or selected assets into Luminex’ consolidated business operations, and the ability to recognize the benefits of Luminex’ acquisitions, reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products, Luminex’ ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, changes in principal members of Luminex’ management staff, potential shortages, or increases in costs, of components or other disruptions to Luminex’ manufacturing operations, competition and competitive technologies utilized by Luminex’ competitors, Luminex’ ability to successfully launch new products in a timely manner, Luminex’ increasing dependency on information technology to enable Luminex to improve the effectiveness of Luminex’ operations and to monitor financial accuracy and efficiency, the implementation, including any modification, of Luminex’ strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex, and risks relating to Luminex’ foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; the burden of monitoring and complying with foreign and international laws and treaties; and the burden of complying with and change in international taxation policies, as well as the risks discussed under the heading "Risk Factors" in Luminex’s Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements, including the financial guidance and 2015 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.




LUMINEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
 
 
 
 
 
September 30,
 
December 31,
 
2015
 
2014
 
(unaudited)
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
119,553

 
$
91,694

Short-term investments
12,006

 
—

Accounts receivable, net
26,161

 
28,272

Inventories, net
29,315

 
36,616

Deferred income taxes
5,125

 
12,203

Prepaids and other
9,694

 
8,235

Total current assets
201,854

 
177,020

Property and equipment, net
48,037

 
39,945

Intangible assets, net
53,927

 
56,382

Deferred income taxes
15,129

 
15,400

Long-term investments
4,003

 
15,975

Goodwill
49,619

 
49,619

Other
3,758

 
3,185

Total assets
376,327

 
357,526

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
9,283

 
$
11,841

Accrued liabilities
13,005

 
14,118

Deferred revenue
4,373

 
4,407

Total current liabilities
26,661

 
30,366

Deferred revenue
2,119

 
2,297

Other
5,041

 
4,869

Total liabilities
33,821

 
37,532

Stockholders' equity:
 
 
 
Common stock
42

 
42

Additional paid-in capital
315,803

 
309,424

Accumulated other comprehensive loss
(1,095
)
 
(744
)
Retained earnings
27,756

 
11,272

Total stockholders' equity
342,506

 
319,994

Total liabilities and stockholders' equity
$
376,327

 
$
357,526

 
 
 
 




LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
 
 
 
 
 
 
 
 
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2015
 
2014
 
2015
 
2014
 
(unaudited)
 
(unaudited)
 
 
 
 
 
 
 
 
Revenue
$
60,601

 
$
56,684

 
$
177,259

 
$
168,877

Cost of revenue
18,789

 
17,674

 
51,958

 
51,766

Gross profit
41,812

 
39,010

 
125,301

 
117,111

Operating expenses:
 
 
 
 
 
 
 
Research and development
10,093

 
10,327

 
31,748

 
32,719

Selling, general and administrative
21,236

 
21,423

 
61,740

 
61,838

Amortization of acquired intangible assets
777

 
964

 
2,455

 
2,949

Restructuring costs
—

 
1,300

 
—

 
1,653

Total operating expenses
32,106

 
34,014

 
95,943

 
99,159

Income from operations
9,706

 
4,996

 
29,358

 
17,952

Interest expense from long-term debt
—

 
—

 
—

 
(6
)
Other income, net
13

 
(15
)
 
964

 
(35
)
Settlement of litigation
—

 
—

 
(7,300
)
 
—

Income before income taxes
9,719

 
4,981

 
23,022

 
17,911

Income tax expense
(3,317
)
 
569

 
(6,538
)
 
(1,670
)
Net income
$
6,402

 
$
5,550

 
$
16,484

 
$
16,241

Net income per share, basic
$
0.15

 
$
0.13

 
$
0.39

 
$
0.39

Shares used in computing net income per share, basic
42,152

 
41,714

 
42,041

 
41,496

Net income per share, diluted
$
0.15

 
$
0.13

 
$
0.39

 
$
0.39

Shares used in computing net income per share, diluted
42,556

 
42,381

 
42,354

 
42,127






LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
 
 
 
 
 
 
 
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2015
 
2014
 
2015
 
2014
 
(unaudited)
 
(unaudited)
Cash flows from operating activities:
 
 
 
 
 
 
 
Net income
$
6,402

 
$
5,550

 
$
16,484

 
$
16,241

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
 
 
Depreciation and amortization
3,411

 
3,400

 
9,733

 
10,935

Stock-based compensation
3,099

 
2,622

 
7,768

 
7,052

Deferred income tax (benefit) expense
176

 
(3,568
)
 
6,207

 
(1,048
)
Excess income tax (benefit) expense from employee stock-based awards
14

 
(1,315
)
 
1,005

 
(1,315
)
(Gain) loss on sale or disposal of assets
(62
)
 
48

 
(743
)
 
231

Non-cash restructuring charges
—

 
1,192

 
—

 
2,388

Other
(25
)
 
(28
)
 
(128
)
 
(360
)
Changes in operating assets and liabilities:
 
 
 
 
 
 
 
Accounts receivable, net
(3,985
)
 
203

 
2,101

 
3,742

Inventories, net
3,364

 
(1,943
)
 
7,414

 
(3,465
)
Other assets
764

 
(829
)
 
(1,629
)
 
(792
)
Accounts payable
1,238

 
1,227

 
(2,536
)
 
(878
)
Accrued liabilities
(3,466
)
 
4,922

 
(3,078
)
 
407

Deferred revenue
(36
)
 
46

 
(212
)
 
53

Net cash provided by operating activities
10,894

 
11,527

 
42,386

 
33,191

Cash flows from investing activities:
 
 
 
 
 
 
 
Purchases of available-for-sale securities
—

 
(8,000
)
 
—

 
(10,996
)
Sales and maturities of available-for-sale securities
—

 
2,996

 
—

 
7,509

Purchase of property and equipment
(2,731
)
 
(5,540
)
 
(15,299
)
 
(11,795
)
Proceeds from sale of assets
—

 
5

 
893

 
44

Acquired technology rights
(650
)
 
—

 
(852
)
 
(64
)
Net cash used in investing activities
(3,381
)
 
(10,539
)
 
(15,258
)
 
(15,302
)
Cash flows from financing activities:
 
 
 
 
 
 
 
Payments on debt
—

 
—

 
—

 
(1,621
)
Proceeds from employee stock plans and issuance of common stock
977

 
327

 
1,690

 
3,807

Excess income tax (benefit) expense from employee stock-based awards
(14
)
 
1,315

 
(1,005
)
 
1,315

Net cash provided by financing activities
963

 
1,642

 
685

 
3,501

Effect of foreign currency exchange rate on cash
13

 
(217
)
 
46

 
(191
)
Change in cash and cash equivalents
8,489

 
2,413

 
27,859

 
21,199

Cash and cash equivalents, beginning of period
111,064

 
86,710

 
91,694

 
67,924

Cash and cash equivalents, end of period
$
119,553

 
$
89,123

 
$
119,553

 
$
89,123

 
 
 
 
 
 
 
 




LUMINEX CORPORATION
NON-GAAP RECONCILIATION
(in thousands, except per share amounts)
 
 
 
 
 
 
 
 
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2015
 
2014
 
2015
 
2014
 
(unaudited)
 
(unaudited)
 
 
 
 
 
 
 
 
Income from operations
$
9,706

 
$
4,996

 
$
29,358

 
$
17,952

Stock-based compensation
3,099

 
2,622

 
7,768

 
7,052

Amortization of acquired intangible assets
777

 
964

 
2,455

 
2,949

Costs associated with legal proceedings
10

 
1,028

 
630

 
2,628

Severance costs
90

 
942

 
284

 
987

Restructuring costs
—

 
1,332

 
—

 
2,652

Adjusted income from operations
$
13,682

 
$
11,884

 
$
40,495

 
$
34,220

Interest expense from long-term debt
—

 
—

 
—

 
(6
)
Other income, net
13

 
(15
)
 
964

 
(35
)
Gain on sale of cost method equity investment
—

 
—

 
(892
)
 
—

Income tax expense
(3,317
)
 
569

 
(6,538
)
 
(1,670
)
Income tax effect of above adjusting items
(1,115
)
 
(941
)
 
(3,588
)
 
(1,649
)
Income tax benefit from intercompany debt cancellation
—

 
—

 
—

 
(994
)
Adjusted net income
$
9,263

 
$
11,497

 
$
30,441

 
$
29,866

Adjusted net income per share, basic
$
0.22

 
$
0.28

 
$
0.72

 
$
0.72

Shares used in computing adjusted net income per share, basic
42,152

 
41,714

 
42,041

 
41,496

Adjusted net income per share, diluted
$
0.22

 
$
0.27

 
$
0.72

 
$
0.71

Shares used in computing adjusted net income per share, diluted
42,556

 
42,381

 
42,354

 
42,127


The Company makes reference in this release to “non-GAAP operating income” and “non-GAAP net income” which excludes stock-based compensation expense, amortization of acquired intangible assets and the impact of costs associated with legal proceedings, which are unpredictable and can vary significantly from period to period, including costs associated with litigation against ENZO Life Sciences, Inc. and Irori Technologies, Inc. discussed in the Legal Proceedings section of our previously filed 10-K and 10-Qs and certain other recurring and non-recurring expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company’s ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company’s past financial performance and prospects for the future. In addition, the Company’s management uses such non-GAAP measures internally to evaluate and assess its core operations and to make ongoing operating decisions. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepared in accordance with GAAP.








Stock widget

Investing forum

LUMINEX CORP Reports